Benzinga | Nov 5, 2020 05:00PM EST

Spero Therapeutics Q3 EPS $(0.86) Beats $(0.87) Estimate, Sales $4.00M Beat $3.20M Estimate

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.87) by 1.15 percent. This is a 9.47 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $4.00 million which beat the analyst consensus estimate of $3.20 million by 24.84 percent. This is a 13.96 percent decrease over sales of $4.64 million the same period last year.